Technical Analysis for CSTL - Castle Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| 200 DMA Support | Bullish | 4.25% | |
| Gapped Down | Weakness | 4.25% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.42% | |
| NR7 | Range Contraction | 2.42% | |
| Narrow Range Bar | Range Contraction | 2.42% | |
| Multiple of Ten Bearish | Other | 2.42% | |
| Inside Day | Range Contraction | 2.42% |
| Alert | Time |
|---|---|
| Rose Above 20 DMA | about 11 hours ago |
| Up 5% | about 11 hours ago |
| Up 1 ATR | about 11 hours ago |
| Up 3% | about 12 hours ago |
| 60 Minute Opening Range Breakout | about 13 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/01/2024
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Melanoma Medical Test Gene Expression Metastasis Dsw Uveal Melanoma
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Melanoma Medical Test Gene Expression Metastasis Dsw Uveal Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.7 |
| 52 Week Low | 9.2601 |
| Average Volume | 235,448 |
| 200-Day Moving Average | 19.13 |
| 50-Day Moving Average | 21.14 |
| 20-Day Moving Average | 20.33 |
| 10-Day Moving Average | 19.49 |
| Average True Range | 0.94 |
| RSI (14) | 50.25 |
| ADX | 17.36 |
| +DI | 25.11 |
| -DI | 25.53 |
| Chandelier Exit (Long, 3 ATRs) | 19.85 |
| Chandelier Exit (Short, 3 ATRs) | 21.32 |
| Upper Bollinger Bands | 22.37 |
| Lower Bollinger Band | 18.29 |
| Percent B (%b) | 0.5 |
| BandWidth | 20.11 |
| MACD Line | -0.38 |
| MACD Signal Line | -0.43 |
| MACD Histogram | 0.0499 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.49 | ||||
| Resistance 3 (R3) | 22.40 | 21.58 | 22.13 | ||
| Resistance 2 (R2) | 21.58 | 21.04 | 21.63 | 22.01 | |
| Resistance 1 (R1) | 20.96 | 20.70 | 21.27 | 21.06 | 21.89 |
| Pivot Point | 20.15 | 20.15 | 20.30 | 20.20 | 20.15 |
| Support 1 (S1) | 19.53 | 19.60 | 19.84 | 19.62 | 18.79 |
| Support 2 (S2) | 18.71 | 19.26 | 18.76 | 18.67 | |
| Support 3 (S3) | 18.09 | 18.71 | 18.55 | ||
| Support 4 (S4) | 18.19 |
